Wayne Yen-Hwa Chang

Wayne Yen-Hwa Chang
Education ● MD, Taipei Medical University, Taiwan ● PhD, Graduate Institute of Clinical Medical Science, Chang Gung University, Taoyuan, Taiwan ● Post-doc, research fellow, Department of urology, Johns Hopkins University, USA Experiences ● Attending staff, Taipei Veterans General Hospital, Taiwan ● Chief, Division of urology, Taipei Veterans General Hospital, Taiwan Current Appointment ● Attending physician, Taipei Veterans General Hospital, Taiwan ● Associate Professor, School of Medicine, College of Medicine, National Yang Ming Chiao Tung University ● Director, Taiwan Urological Association

15th August 2025

Time Session
15:30
17:00
Industry Symposium 5 【MSD】
Current Trends in Management of Advanced Urothelial Carcinoma
TICC - 1F 101B

16th August 2025

Time Session
12:00
13:00
Luncheon Symposium 19【Bayer】
Latest Advances in mHSPC to Fight Tumor Heterogeneity: Experience from Australia and Japan
TICC - 3F South Lounge
13:30
15:00
Industry Symposium 10 【Astellas】
Recent Advancements in Muscle-Invasive Urothelial Carcinoma
  • Welcome
    Wayne Yen-Hwa ChangTaiwan Moderator
  • Recent Advancements in Muscle-Invasive Urothelial Carcimoma
    Cheng-Kuang YangTaiwan Speaker Robotic Radical Prostatectomy: Trying to Fit the Right Surgery to the Right PatientDefinitive treatment for localized prostate cancer included radical prostatectomy and radiation. Successful criteria of radical prostatectomy have to meet oncology control, not persistent PSA after surgery without salvage therapy. MRI imaging stage and PSA density are predictors for short‐term BCR after prostatectomy. NCCN‐defined high‐risk patients with a high initial PSA 28 density, imaging stage (T3aN0M0 and T3bN0M0), and 29 pathologic stage (any N1) had a higher risk of BCR when 30 compared with other patients with undetectable PSA, while 31 those with pathologic stage (T3bN0M0 or any N1) displayed 32 a higher risk of postoperatively detectable PSA. These find‐ 33 ings may help urologists to identify patients for whom active 34 therapeutic protocols are necessary.
  • Panel Discussion - Can We Adapt the Treatment Paradigm Shift in Early Stage UC?
    Wayne Yen-Hwa ChangTaiwan Moderator
    Cheng-Kuang YangTaiwan Speaker Robotic Radical Prostatectomy: Trying to Fit the Right Surgery to the Right PatientDefinitive treatment for localized prostate cancer included radical prostatectomy and radiation. Successful criteria of radical prostatectomy have to meet oncology control, not persistent PSA after surgery without salvage therapy. MRI imaging stage and PSA density are predictors for short‐term BCR after prostatectomy. NCCN‐defined high‐risk patients with a high initial PSA 28 density, imaging stage (T3aN0M0 and T3bN0M0), and 29 pathologic stage (any N1) had a higher risk of BCR when 30 compared with other patients with undetectable PSA, while 31 those with pathologic stage (T3bN0M0 or any N1) displayed 32 a higher risk of postoperatively detectable PSA. These find‐ 33 ings may help urologists to identify patients for whom active 34 therapeutic protocols are necessary.
    Po-Jung SuTaiwan Speaker
    Yu-Chieh TsaiTaiwan Speaker
  • Closing
TICC - 1F 101C